Regulatory Index News w/c 03 Dec 2018

Here is a selection of this week's latest news from around the world

 

Takeda shareholders back £46bn Shire takeover

Takeda Pharmaceutical has won shareholder approval for a £46bn ($59bn) takeover of UK-listed drugmaker Shire, clearing the way for Japan's largest corporate acquisition.

To read more follow this BBC News link

 

Janssen unveils new data backing wider use of Darzalex

Janssen has unveiled data from a late-stage trial backing earlier use of its first-in-class biologic daratumumab (marketed as Darzalex) in patients with mutiple myeloma.

To read more follow this PharmaTimes link

     
 

Johnson & Johnson pays $300m to develop cusatuzumab

Johnson & Johnson's Janssen has entered into an agreement potentially worth up to $1.6 billion to develop and market Argenx' cusatuzumab for a number of cancers, including haematological malignancies.

To read more follow this PharmaTimes link

 

ASH18: CAR-T shows up in early CLL test

A CAR-T cell therapy acquired by Celgene earlier this year could have a path forward in chronic lymphocytic leukemia (CLL), showing initial signs of efficacy in a small group of heavily pretreated patients with the blood cancer. 

To read more follow this BioPharmaDive link

     
 

Eli Lilly's former drug yields Phase 2 win for Vanda Pharma

Vanda Pharmaceuticals on Monday rolled out positive Phase 2 data supporting its experimental drug for gastroparesis, a condition that's gone without new treatment options for nearly four decades. 

To read more follow this BioPharmaDive link

 

Roche's Hemlibra shows sustained bleed control in children

Roche's Hemlibra has shown sustained bleed control in a late-stage trial involving 85 children with haemophilia A.

To read more follow this BioPharmaDive link

 
For more Regulatory Index news click here
L O

Author

Lorna Osborn

Date Published

03rd December 2018

Come and join our community!

We are ready and waiting for you

We use cookies. By continuing to browse the site or closing this message you are agreeing to our Terms and Privacy Policy

ACCEPT and Hide This Message